Patent ID: 9028866
Filing Date: 2015-05-12
Classification: A61K,A61P

Abstract:
1. A method of achieving a blood, serum, or plasma level in a subject of at least about 4 μg/mL of an N-methylol transfer agent comprising taurolidine, taurultam, a derivative of taurolidine or taurultam, or a combination thereof, comprising administering to said subject a capsule comprising the N-methylol transfer agent and a pharmaceutically acceptable targeted release carrier, said targeted release carrier providing an efficacious blood, serum or plasma level of said N-methylol transfer agent in said subject, after oral administration of said capsule, to treat a disease in said subject, wherein, after said oral administration, said carrier (a) carries said agent substantially intact through said subject's stomach and releases said agent into said subject's duodenum or jejunum, wherein said agent enters the subject's bloodstream through said duodenum or jejunum, (b) releases said agent at a pH of about 5.4 to about 6.5, wherein said agent enters the subject's bloodstream, or (c) both.